



PTO/SB/08a/b (08-03)  
Approved for use through 07/31/2008. OMB 0851-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE  
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

|   |   |    |                          |                   |
|---|---|----|--------------------------|-------------------|
| Substitute for form 1449A/B/PTO   |   |    | <b>Complete If Known</b> |                   |
| <b>INFORMATION DISCLOSURE<br/>STATEMENT BY APPLICANT</b><br><br>(Use as many sheets as necessary) |   |    | Application Number       | 10/782244         |
|   |   |    | Filing Date              | February 18, 2004 |
|   |   |    | First Named Inventor     | David M. Sabatini |
|   |   |    | Art Unit                 | 1653              |
|   |   |    | Examiner Name            | A. B. Rooke       |
|   |   |    | Attorney Docket Number   | WIBL-P01-010      |
| Sheet   | 1 | of | 2                        |                   |


| U.S. PATENT DOCUMENTS |                       |   |                                |  |   |
|-----------------------|-----------------------|---|--------------------------------|--|---|
| Examiner Initials*    | Cite No. <sup>1</sup> | Document Number<br>Number-Kind Code <sup>2</sup> (if known) | Publication Date<br>MM-DD-YYYY | Name of Patentee or<br>Applicant of Cited Document | Pages, Columns, Lines, Where<br>Relevant Passages or Relevant<br>Figures Appear |
|                       |                       |   |                                |  |   |

| FOREIGN PATENT DOCUMENTS |                       |  |                                   |  |  |
|--------------------------|-----------------------|--|-----------------------------------|--|--|
| Examiner Initials*       | Cite No. <sup>1</sup> | Foreign Patent Document<br>Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known) | Publication<br>Date<br>MM-DD-YYYY | Name of Patentee or<br>Applicant of Cited Document | Pages, Columns, Lines,<br>Where Relevant Passages<br>or Relevant Figures Appear T <sup>6</sup> |
|                          |                       |  |                                   |  |  |

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language translation is attached.

| NON PATENT LITERATURE DOCUMENTS |                       |   |  |                |
|---------------------------------|-----------------------|---|--|----------------|
| Examiner Initials               | Cite No. <sup>1</sup> | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. |  | T <sup>2</sup> |
| AR                              | CA                    | Chen, J., et al., "Identification of an 11-kDa FKBP12-rapamycin-binding domain within the 289-kDa FKBP12-rapamycin-associated protein and characterization of a critical serine residue," Proc. Natl. Acad. Sci. USA, 92:4947-4951 (1995).                      |  |                |
|                                 | CB                    | Dennis, P.B., et al., "Mammalian TOR: A Homeostatic ATP Sensor," Science, 294:1102-1105 (2001).   |  |                |
|                                 | CC                    | Gao, X., et al., "Tsc tumour suppressor proteins antagonize amino-acid-TOR signalling," Nature Cell Biology, 4:699-704 (2002).  |  |                |
|                                 | CD                    | Hara, K., et al., "Raptor, a Binding Partner of Target of Rapamycin (TOR), Mediates TOR Action," Cell, 110:177-189 (2002).  |  |                |
|                                 | CE                    | Hentges, K.E., et al., "FRAP/mTOR is required for proliferation and patterning during embryonic development in the mouse," PNAS, 98(24):13796-13801 (2001).   |  |                |
|                                 | CF                    | Keith, C.T. and Schreiber, S.L., Science 270 (5233): 50-1 (abstract)  |  |                |
|                                 | CG                    | Kim, D-H., et al., "GβL, a Positive Regulator of the Rapamycin-Sensitive Pathway Required for the Nutrient-Sensitive Interaction between Raptor and mTOR," Molecular Cell, 11:895-904 (2003).   |  |                |
|                                 | CH                    | Kim, D-H., et al., "mTOR Interacts with Raptor to Form a Nutrient-Sensitive Complex that Signals to the Cell Growth Machinery," Cell, 110(2):163-175 (2002).  |  |                |
|                                 | CI                    | Kwiatkowski, D.J., et al., "A mouse model of TSC1 reveals sex-dependent lethality from liver hemangiomas, and up-regulation of p70S6 kinase activity in Tsc1 null cells," Human Molecular Genetics, 11(5):525-534 (2002).                                       |  |                |
|                                 | CJ                    | Liu, Z., et al., "RTG-dependent mitochondria to nucleus signaling is negatively regulated by the seven WD-repeat protein Lst8p," The EMBO Journal, 20(24):7209-7219 (2001).   |  |                |
|                                 | CK                    | Mammalian Gene Collection (MGC) Program Team: "Generation and Initial Analysis of More Than 15,000 Full-Length Human and Mouse cDNA Sequences", Proceedings of the National Academy of Sciences of USA, National Academy of Science, 99(26): 16899-16903 (2002) |  |                |
|                                 | CL                    | Neshat, M.S., et al., "Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR," PNAS, 98(18):10314-10319 (2001).  |  |                |
|                                 | CM                    | Nojima, H., et al., "The Mammalian Target of Rapamycin (mTOR) Partner, Raptor, Binds the  |  |                |

|                                 |                |                 |            |
|---------------------------------|----------------|-----------------|------------|
| Examiner Signature<br>8683037_1 | Agnes B. Rooke | Date Considered | 05/25/2005 |
|---------------------------------|----------------|-----------------|------------|



PTO/SB/08a/b (08-03)

Approved for use through 07/31/2008. OMB 0851-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

|   |   |    |   |                          |                   |
|---|---|----|---|--------------------------|-------------------|
| <b>Substitute for form 1449A/B/PTO</b><br><br><b>INFORMATION DISCLOSURE<br/>STATEMENT BY APPLICANT</b><br><br>(Use as many sheets as necessary) |   |    |   | <b>Complete If Known</b> |                   |
|   |   |    |   | Application Number       | 10/782244         |
|   |   |    |   | Filing Date              | February 18, 2004 |
|   |   |    |   | First Named Inventor     | David M. Sabatini |
|   |   |    |   | Art Unit                 | 1653              |
|   |   |    |   | Examiner Name            | A. B. Rooke       |
| Sheet   | 2 | of | 2 | Attorney Docket Number   | WIBL-P01-010      |

|    |    |  |  |
|----|----|--|--|
| AR |    | mTOR Substrates p70 S6 Kinase and 4E-BP1 through Their TOR Signaling (TOS) Motif," Journal of Biological Chemistry, 278(18):15461-15464 (2003).  |  |
| AR | CN | Ochotorena, I.L., et al., "Conserved Wat1/Pop3 WD-repeat protein of fission yeast secures genome stability through microtubule integrity and may be involved in mRNA maturation," Journal of Cell Science, 114:2911-2920 (2001). |  |
|    | CO | Podsypanina, K., et al., "An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/- mice," PNAS, 98(18):10320-10325 (2001).  |  |
|    | CP | Riken Genome Exploration Research Group Phase II Team and Fantom Consortium: "Functional Annotation of a Full-Length Mouse CDNA Collection", Nature, MacMillan Journals Ltd., London, GB, 409(6821): 685-690 (2001)              |  |
|    | CQ | Roberg, K.J., et al., "Control of Amino Acid Permease Sorting in the Late Secretory Pathway of Saccharomyces cerevisiae by SEC13, LST4, LST7 and LST8," Genetics, 147:1569-1584 (1997).  |  |
|    | CR | Rodgers, B.D., et al., "Insulin regulation of a novel WD-40 repeat protein in adipocytes," Journal of Endocrinology, 168:325-332 (2001).   |  |
|    | CS | Sabatini, D.M., et al., "RAFT1: A mammalian protein that binds to FKBP12 in a rapamycin-dependent fashion and is homologous to yeast TORs," Cell, 78(1):35-43 (1994) abstract.   |  |
|    | CT | Sarbassov, Dos D., et al., "Rictor, a Novel Binding Partner of mTOR, Defines a Rapamycin-Insensitive and Raptor-Independent Pathway that Regulates the Cytoskeleton", Current Biology, 14: 1296-1302 (2004)                      |  |
|    | CU | Schmeizle, T., et al., "TOR, a Central Controller of Cell Growth," Cell, 103:253-262 (2000).   |  |
| ✓  | CV | Vogt, P.K., "PI 3-kinase, mTOR, protein synthesis and cancer," Trends in Molecular Medicine, 7(11):482-484 (2001).   |  |

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

|                    |                |                 |            |
|--------------------|----------------|-----------------|------------|
| Examiner Signature | Agnes B. Rooke | Date Considered | 05/25/2005 |
|--------------------|----------------|-----------------|------------|

9883037\_1